PCNA expression in RPE cells and inhibition of antisense oligonucleotides encoding PCNA mRNA to gene expression and proliferation of RPE cells
- VernacularTitle:增生细胞核抗原在视网膜色素上皮细胞表达及其反义寡核苷酸的抑制作用
- Author:
Jianbin CHEN
;
Shuiqing ZENG
;
Lili XU
- Publication Type:Journal Article
- Keywords:
Pigment epithelium of eye;
Oligonucleotides,antisense;
Proliferating cell nuclear antigen;
Gene expression
- From:
Chinese Journal of Ocular Fundus Diseases
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate proliferating cell nuclear antigen (PCNA) gene expression in retinal pigment epithelium (RPE) cells and inhibition of antisense oligonucleotides(AS OND) encoding PCNA mRNA to gene expression and proliferation of RPE cells, so as to search for new genetic therapy way for pro1iferative vitreoretinopathy (PVR). Methods (1) Rabbit RPE cells cultured in vitro were detected for PCNA expression by streptoavidin biotin enzyme complex (SABC) immunohistochemistry at several times. (2) The liposome mediated synthetic antisense oligodeoxynucleotides (AS ODN) and sense oligodeoxynucleotides (S ODN) encoding PCNA were delivered to the RPE cells at different concentrations, then PCNA expresstion were detected by immunohistochemistry. (3) Exposed to different concentrations of AS ODN and S ODN, growth activity and suppressive rate of RPE cells were measured by methyl thiazolyl tetrazolium (MTT) methods. Results (1) PCNA were expressed in RPE cells, culmination in 48 hours of culture. (2) PCNA expression were markedly suppressed in the RPE cells treated with 0.28 and 1.12 ?mol/L PCNA AS ODN . (3) 0.28 ?mol/L and 1.12 ?mol/L PCNA AS ODN significantly inhibited proliferative activity of RPE cells in a dose dependent manner, the arrest rates of cellular growth reached 53% and 81% respectively. Conclusion AS ODN complementary to PCNA mRNA at some concentration can sequence specifically suppress PCNA expression in RPE cells and cellular proliferative activity, and show potential application to further experimental study for PVR genetic medication.
